Kura Oncology, Inc.
For the period ended Dec 31, 2025. Filed Mar 5, 2026.
View on SEC.govAbout this filing
A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.
FY2025 · Filed Mar 5, 2026
KURA$7.57+4.1%Stored close · as of Nov 9, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Statements of Stockholders’ Equity
(In thousands)
| Accumulated | ||||||
|---|---|---|---|---|---|---|
| Additional · Other · Total | ||||||
| Common Stock · Paid-In · Comprehensive · Accumulated · Stockholders’ | ||||||
| Shares | Par Value | Capital | Income (Loss) | Deficit | Equity | |
| Balance as of December 31, 2022 | 68,314 | $7 | $997,111 | $(8,032) | $(568,808) | $420,278 |
| Issuance of common stock, net of offering costs | 5,661 | — | 60,919 | — | — | 60,919 |
| Issuance of pre-funded warrants to purchase common stock, net of offering costs | — | — | 32,658 | — | — | 32,658 |
| Share-based compensation expense | — | — | 28,082 | — | — | 28,082 |
| Issuance of common stock under equity plans | 375 | — | 1,206 | — | — | 1,206 |
| Other comprehensive income | — | — | — | 6,761 | — | 6,761 |
| Net loss | — | — | — | — | (152,631) | (152,631) |
| Balance as of December 31, 2023 | 74,350 | 7 | 1,119,976 | (1,271) | (721,439) | 397,273 |
| Issuance of common stock, net of offering costs | 1,377 | — | 23,087 | — | — | 23,087 |
| Issuance of pre-funded warrants to purchase common stock, net of offering costs | — | — | 122,726 | — | — | 122,726 |
| Share-based compensation expense | — | — | 33,897 | — | — | 33,897 |
| Exercise of pre-funded warrants | 1,420 | 1 | — | — | — | 1 |
| Issuance of common stock under equity plans | 1,082 | — | 8,604 | — | — | 8,604 |
| Other comprehensive income | — | — | — | 2,035 | — | 2,035 |
| Net loss | — | — | — | — | (173,983) | (173,983) |
| Balance as of December 31, 2024 | 78,229 | 8 | 1,308,290 | 764 | (895,422) | 413,640 |
| Share-based compensation expense | — | — | 37,108 | — | — | 37,108 |
| Exercise of pre-funded warrants | 8,516 | 1 | (1) | — | — | — |
| Issuance of common stock under equity plans | 1,110 | — | 1,793 | — | — | 1,793 |
| Other comprehensive income | — | — | — | 260 | — | 260 |
| Net loss | — | — | — | — | (278,666) | (278,666) |
| Balance as of December 31, 2025 | 87,855 | $9 | $1,347,190 | $1,024 | $(1,174,088) | $174,135 |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.